Llmenos al (972) 702-8888 o contctenos en lnea para programar su cita
The SURMOUNT-5 head-to-head trial directly compared tirzepatide to semaglutide and found 47% greater weight loss with tirzepatide at 72 weeks
Whilst these results are notable, direct comparisons with currently approved agents should be interpreted with caution: such comparisons are indirect, based on different trial designs, populations, durations, and background interventions (including lifestyle counselling provided alongside study drug), and cannot be treated as equivalent to head-to-head evidence
715-725.e3, Apr
Important to understand: Compounded GLP-1 medications are not FDA-approved products and dont go through the same pre-market testing, consistency checks, or safety review as brand-name drugs
Our program pairs medication with nutrition coaching and structured follow-ups for safe, sustainable progress